The augmentation of ROS has been shown to activate c-jun N terminal kinase 1 (JNK1) [35], which is implicated in obesity-induced insulin resistance and decreased compensatory insulin secretion, both of which are key features of type 2 diabetes [36]. Here, INS is linked to type 2 diabetes mellitus.